Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study

•Evidence of transient sensory symptoms in recipients of BNT162b2 mRNA COVID-19 is scarce.•Sensory symptom frequency in first dose recipients of BNT162b2 who reported an AEFI is 3.4% (95% CI 3.1% to 3.8%).•Arms and face/neck are the most commonly affected sites (61% and 36.2%, respectively).•Healthc...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2021-11, Vol.39 (48), p.6975-6979
Main Authors: García-Grimshaw, Miguel, Ceballos-Liceaga, Santa Elizabeth, Michel-Chávez, Anaclara, García-Alanis, Mario, Cadena-Fernández, Arturo, Galnares-Olalde, Javier Andrés, Carbajal-Sandoval, Guillermo, Carrillo-García, Daniel Amado, Hernández-Valdivia, Noé, Hernández-Vanegas, Laura E., Saniger-Alba, María del Mar, Gutierrez-Romero, Alonso, Díaz-Ortega, José Luis, Reyes-Terán, Gustavo, López-Gatell, Hugo, Flores-Silva, Fernando Daniel, Cantú-Brito, Carlos, Chiquete, Erwin, Arauz, Antonio, Valdés-Ferrer, Sergio Iván
Format: Article
Language:English
Subjects:
Adverse event
AEFI
BNT162 Vaccine
BNT162b2
Case-Control Studies
Coronaviruses
COVID-19
COVID-19 Vaccines
Datasets
Epidemiology
Guillain-Barre syndrome
Health surveillance
Humans
Immunization
Immunization stress-related response
Infections
Influenza
Medical personnel
mRNA
Pandemics
Paresthesia
RNA, Messenger
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Short Communication
Stress
Topography
Vaccines
Vaccines - adverse effects
Workers
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Evidence of transient sensory symptoms in recipients of BNT162b2 mRNA COVID-19 is scarce.•Sensory symptom frequency in first dose recipients of BNT162b2 who reported an AEFI is 3.4% (95% CI 3.1% to 3.8%).•Arms and face/neck are the most commonly affected sites (61% and 36.2%, respectively).•Healthcare workers have lower odds for reporting sensory symptoms (aOR 0.54; 95% CI 0.40–0.72;p 
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2021.10.058